Steigert Sebastian, Brouwers Joachim, Vanuytsel Tim, Borde Anders, Karlsson Eva M, Olivefors Astrid, Tannergren Christer, Augustijns Patrick
Drug Delivery and Disposition, KU Leuven, Gasthuisberg ON2, Herestraat 49 - box 921, Leuven 3000, Belgium.
Translational Research Center for Gastrointestinal Disorders, TARGID, KU Leuven, Gasthuisberg ON1, Herestraat 49 - box 701, Leuven 3000, Belgium.
Mol Pharm. 2025 Aug 4;22(8):4855-4864. doi: 10.1021/acs.molpharmaceut.5c00500. Epub 2025 Jun 26.
Colonic drug absorption is a prerequisite for a drug's suitability for colon-targeted and extended-release formulations. Since drug solubility is a key factor for uptake in the gastrointestinal tract, reliably estimating solubility in the human colon is essential for determining the feasibility of such formulation approaches. To date, our understanding of colonic drug solubility, how it compares to the proximal small intestine, and how it is linked to luminal fluid composition is limited by the scarcity of reference data available. Therefore, this study aimed to measure and compare the apparent solubility of eight drugs with varying physicochemical properties (apixaban, danoprevir, dexloxiglumide, febuxostat, fenofibrate, rofleponide, ticagrelor and tofacitinib) in pooled aspirates from the proximal human colon and small intestine, along with simulated media and buffers commonly used in solubility assessment. Additionally, the composition of the pooled luminal fluids was characterized. Whereas solubility in colonic and small intestinal fluids was comparable for most drugs, the small intestine's solubilizing capacity clearly exceeded that of the colon for the lipophilic drugs fenofibrate and ticagrelor. Extensive degradation of danoprevir was observed in both luminal fluids. Prediction of small intestinal solubility of the lipophilic compounds fenofibrate and ticagrelor was improved in fasted state simulated intestinal fluid compared to blank buffer, although the solubilizing capacity of the human fluids was only captured partially. Fasted state simulated colonic fluid solely improved the colonic solubility prediction of fenofibrate, while the prediction of ticagrelor remained outside the 2-fold prediction error threshold. Solubilities of all other drugs were predicted reasonably well in blank buffers and simulated media. The results generated in this study may serve as reference data for the validation of improved in vitro and in silico tools for colonic drug solubility prediction.
结肠药物吸收是药物适用于结肠靶向和缓释制剂的前提条件。由于药物溶解度是胃肠道吸收的关键因素,可靠地估计人结肠中的溶解度对于确定此类制剂方法的可行性至关重要。迄今为止,我们对结肠药物溶解度、其与近端小肠的比较以及与肠腔液成分的联系的了解受到现有参考数据稀缺的限制。因此,本研究旨在测量和比较八种具有不同理化性质的药物(阿哌沙班、达诺普韦、右旋洛谷酰胺、非布司他、非诺贝特、罗氟司特、替卡格雷洛和托法替布)在人近端结肠和小肠的混合抽吸物、溶解度评估中常用的模拟介质和缓冲液中的表观溶解度。此外,还对混合肠腔液的成分进行了表征。虽然大多数药物在结肠和小肠液中的溶解度相当,但对于亲脂性药物非诺贝特和替卡格雷洛,小肠的溶解能力明显超过结肠。在两种肠腔液中均观察到达诺普韦的广泛降解。与空白缓冲液相比,在禁食状态模拟肠液中亲脂性化合物非诺贝特和替卡格雷洛的小肠溶解度预测有所改善,尽管人体液的溶解能力仅部分得到体现。禁食状态模拟结肠液仅改善了非诺贝特的结肠溶解度预测,而替卡格雷洛的预测仍超出2倍预测误差阈值。所有其他药物在空白缓冲液和模拟介质中的溶解度预测相当良好。本研究产生的结果可作为验证改进的结肠药物溶解度预测体外和计算机工具的参考数据。